Menta Capital’s Agile Therapeutics AGRX Stock Holding History

Menta Capital’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-5	Closed	-$87K	–	836
2015 Q2	$87K	Buy	+5	New	+$107K	0.01%	642

Other funds holding AGRX

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Menta Capital's AGRX Position: Q3 2015 in Review

Menta Capital sold out of Agile Therapeutics (AGRX) in Q3 2015, closing a stake of 5 shares — an estimated $87K sold.

Menta Capital first reported a position in AGRX in Q2 2015 and held it in 1 quarter. The position peaked at $87K in Q2 2015. 45 funds tracked by Wall St. Rank hold AGRX as of Q3 2015.

Menta Capital reported no remaining Agile Therapeutics position as of Q3 2015 after selling out during the quarter.
Menta Capital sold 5 Agile Therapeutics shares in Q3 2015, an estimated $87K.
Menta Capital first reported a position in Agile Therapeutics in Q2 2015 and held it in 1 quarter.
Menta Capital's Agile Therapeutics position peaked at $87K in Q2 2015.
45 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2015.

Based on Menta Capital's 13F filing for Q3 2015, filed 12 Nov 2015.